OVER / UNDER
KXFDAVERVE102-VERV ★ KALSHI ★ MULTI ★ KXFDAVERVE102-VERV ★ KALSHI ★ MULTI ★ KXFDAVERVE102-VERV ★ KALSHI ★ MULTI ★ KXFDAVERVE102-VERV ★ KALSHI ★ MULTI ★ KXFDAVERVE102-VERV ★ KALSHI ★ MULTI ★ KXFDAVERVE102-VERV ★ KALSHI ★ MULTI ★

Will the FDA approve VERVE-102?

Price history — Before 2035

Last 7 days of market YES price (blue) with the fair-price range (orange).

79¢0¢25¢50¢75¢100¢Fri 5/29Sat 5/30Sun 5/31Mon 6/1Tue 6/2Wed 6/3TODAY
market YES fair range
Market price
Before 2035★ BEST79¢
Before 203474¢
Before 203372¢
Before 203270¢
Before 203162¢
Before 203052¢
Kalshi • Volume: 567.1 contracts • Updated 4h agoCloses: 2035-01-01
Kalshi · Science and Technology
OU's Pick
YES · Before 2035
at 79¢
Price gap
Kalshi79¢
OU's fair62¢
17¢ overpriced · pays 1.3×
Confidence
Moderate

The FDA granted Fast Track designation and cleared the IND application for VERVE-102 in early 2025 which accelerates the development timeline for this gene editing therapy.

Wide edge+17¢
Not financial advice. For informational purposes only. Prediction markets involve risk of loss. AI may contain errors.